TG Therapeutics (TGTX) PT Lowered to $13 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to TG Therapeutics (TGTX) PT Lowered to $13 at Goldman Sachs
November 30, 2021 8:54 AM EST
TG Therapeutics (NASDAQ: TGTX) stock price is down nearly 40% today after the company announced the U.S. Food and Drug Administration (FDA) plans to hold a meeting of the Oncologic Drugs Advisory Committee (ODAC).
The Committee will discuss and review pending TGTXs application for the combination of ublituximab and UKONIQ (umbralisib) (known as U2) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma... More
November 30, 2021 7:33 AM EST
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the U.S. Food and Drug Administration (FDA) has notified the Company that it plans to host a meeting of the Oncologic Drugs Advisory Committee (ODAC) in connection with its review of the pending Biologics License Application (BLA)/supplemental New Drug Application (sNDA) for the combination of ublituximab and UKONIQ® (umbralisib) (combination referred to as U2) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, We... More
